CytomX Therapeutics appoints Carlos Campoy as CFO
Mr. Campoy brings over 30 years of financial and leadership experience, the majority from publicly held companies within the healthcare and biopharmaceutical sectors.
Most recently, Mr. Campoy held the position of chief financial officer at Alder BioPharmaceuticals, which was acquired in October 2019 by Lundbeck A/S, where he led the finance organization and readied the company for commercial launch of its lead program, eptinezumab, a recently approved treatment for the prevention of migraine.
Prior to Alder, he held the role of vice president of finance, international at Allergan plc.
Prior to joining Allergan, over the course of an 18-year tenure at Eli Lilly and Company, Mr. Campoy held senior financial leadership positions including most recently as chief financial officer of Eli Lilly Japan K.K.
Mr. Campoy received his M.B.A. in Finance and Decision Information Systems from Indiana University and his B.S. in Management from Faculdade C.C. Administracao de Tupa, in São Paulo, Brazil. ■